[HTML][HTML] 2018 Korean Liver Cancer Association–National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association - Gut and liver, 2019 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth
most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection …
most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection …
2018 Korean Liver Cancer Association-National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth
most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection …
most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection …
[HTML][HTML] Transarterial chemoembolization for hepatocellular carcinoma: 2023 expert consensus-based practical recommendations of the Korean Liver Cancer …
Transarterial chemoembolization (TACE) was introduced in 1977 with the administration of
chemotherapeutic agent to gelatin sponge particles through the hepatic artery in patients …
chemotherapeutic agent to gelatin sponge particles through the hepatic artery in patients …
[HTML][HTML] 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association - Korean Journal of Radiology, 2022 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth
most common cancer among men in South Korea, where the prevalence of chronic hepatitis …
most common cancer among men in South Korea, where the prevalence of chronic hepatitis …
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
JW Park - Clinical and Molecular Hepatology (대한간학회지), 2022 - kiss.kstudy.com
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth
most common cancer among men in South Korea, where the prevalence of chronic hepatitis …
most common cancer among men in South Korea, where the prevalence of chronic hepatitis …
[HTML][HTML] 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association - Journal of Liver Cancer, 2023 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth
most common cancer among men in South Korea, where the prevalence of chronic hepatitis …
most common cancer among men in South Korea, where the prevalence of chronic hepatitis …
[HTML][HTML] Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular …
JN Liu, JJ Li, S Yan, GN Zhang, PS Yi - Frontiers in oncology, 2023 - frontiersin.org
Background: The combination of tyrosine kinase inhibitors (TKIs) and transarterial
chemoembolization (TACE) fulfills an important role in the treatment of unresectable …
chemoembolization (TACE) fulfills an important role in the treatment of unresectable …
[HTML][HTML] Complications related to transarterial treatment of hepatocellular carcinoma: A comprehensive review
HN Lee, D Hyun - Korean Journal of Radiology, 2023 - ncbi.nlm.nih.gov
Currently, various types of transarterial treatments are performed for hepatocellular
carcinoma from the early to advanced stages. Its indications and efficacy have been widely …
carcinoma from the early to advanced stages. Its indications and efficacy have been widely …
Risk factors for postembolization syndrome after transcatheter arterial chemoembolization
M Arslan, S Degirmencioglu - Current Medical Imaging, 2019 - ingentaconnect.com
Background: Transarterial Chemoembolization (TACE) is a minimally invasive treatment in
managing unresectable liver primary neoplasms or liver metastases. Postembolization …
managing unresectable liver primary neoplasms or liver metastases. Postembolization …
Five-years outcome analysis of 142 consecutive hepatocellular carcinoma patients treated with doxorubicin eluting microspheres 30–60 μm: results from a single …
K Malagari, H Moschouris, T Kiakidis… - Cardiovascular and …, 2019 - Springer
Purpose To assess prospectively long-term results of doxorubicin-loaded HepaSphere 30–
60 μm in consecutive patients with hepatocellular carcinoma (HCC) not amenable to …
60 μm in consecutive patients with hepatocellular carcinoma (HCC) not amenable to …